SLC5A2 and type 2 diabetes mellitus: SGLT2 inhibitors are a new class of hypoglycemic agents that compete with glucose for the SGLT2 transporter to lower blood glucose levels, change threshold to concentrations, and enhance urinary glucose excretion (UGE) in patients with type 2 diabetes mellitus (T2DM) (Maurer et al., 2011).